CoQ10 has a history as an adjunctive agent in the treatment of cardiovascular disease. In 1974 CoQ10 was approved in Japan as a treatment of congestive heart failure. Clinical trials have shown CoQ10 to improve heart workload capacity and ejection fraction. Currently, a reliable and reproducible method using highly sensitive HPLC-MS platform for the rapid identification and quantification of ubiquinone in different sample types has been established by the experienced scientists at Creative Proteomics, which can satisfy the needs of academic and industrial study in your lab.